LGND Q1 2024 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M-29.6% YoY

Gross Profit

$20M64.3% margin

Operating Income

$3M9.6% margin

Net Income

$86M278.1% margin

EPS (Diluted)

$4.75

QoQ Revenue Growth

+10.2%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$19M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$914M

Total Liabilities

$107M

Stockholders' Equity

$807M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$44M	-29.6%
Gross Profit	$20M	$40M	-50.5%
Operating Income	$3M	$14M	-79.0%
Net Income	$86M	$42M	+105.3%

Revenue Segments

Royalty

$19M31%

Intangible Royalty Assets

$18M29%

Material Sales, Captisol

$9M15%

Kyprolis

$7M11%

Rylaze

$3M5%

Royalty, Other

$2M3%

Teriparatide Injection

$2M3%

Evomela

$1M2%

Financial Royalty Assets

$738,0001%